Spotlight on itolizumab in the treatment of psoriasis – current perspectives from India
Leelavathy Budamakuntla,1 HV Shree-Lakshmi,1 Akshi Bansal,1 Shankar Kumar Venkatarayaraju2 1Department of Dermatology, Venerology and Leprosy, Bangalore Medical College and Research Institute, Bengaluru, Karnataka 560002, India; 2Department of Endocrinology, MS Diabetes Centre, Indiranagar, Bangalor...
Guardado en:
Autores principales: | Budamakuntla L, Shree-Lakshmi HV, Bansal A, Venkatarayaraju SK |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
Dove Medical Press
2019
|
Materias: | |
Acceso en línea: | https://doaj.org/article/e25f1439d12743b48049eca1d4ffdb28 |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
-
Efficacy and safety of netakimab, a novel anti-IL-17 monoclonal antibody, in patients with moderate to severe plaque psoriasis. Results of a 54-week randomized double-blind placebo-controlled PLANETA clinical trial
por: Luis Puig, et al.
Publicado: (2021) -
Spotlight on risankizumab and its potential in the treatment of plaque psoriasis: evidence to date
por: Machado Á, et al.
Publicado: (2018) -
Secukinumab: Rapid Efficacy in Psoriasis After Primary Failure With Ustekinumab and Adalimumab
por: Aline Lissa Okita, et al.
Publicado: (2020) -
Pustular psoriasis: pathophysiology and current treatment perspectives
por: Benjegerdes KE, et al.
Publicado: (2016) -
Eficacia y seguimiento en el largo plazo de pacientes con psoriasis vulgar moderada a severa en tratamiento con infliximab (Remicade®)
por: Valdés A,María del Pilar, et al.
Publicado: (2006)